Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
Christopher Ernest Maitland GriffithsKim A PappMichael SongMegan MillerYin YouYaung-Kaung ShenChenglong HanAndrew BlauveltPublished in: The Journal of dermatological treatment (2020)
High efficacy response rates were maintained through four years of continuous guselkumab treatment for psoriasis.